Open label naturalistic six month study of aripiprazole in schizophrenia measuring functional outcomes and positive, negative and cognitive symptoms
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Aripiprazole (Primary)
- Indications Psychotic disorders; Schizophrenia
- Focus Therapeutic Use
- Acronyms Double A Study
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 08 Jun 2016 Status changed from recruiting to completed.
- 30 Aug 2011 New trial record